Breaking News, Financial News

Financial Report: Alexion

Revenues up 48% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion   2Q Revenues:  $274.7 million (+48%)   2Q Earnings: $36.3 million (+5%)   YTD Revenues: $519.5 million (+48%)   YTD Earnings: $81.7 million (+33%)   Comments: Revenues were driven by Soliris, which added the indication of atypical hemolytic uremic syndrome late last year. R&D expenses rose 70% to $60 million as the company advanced several drugs in its pipeline....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters